Diabetic macular edema
The role of anti-VEGF agents in the management and the interest of prevention
Versandkostenfrei!
Versandfertig in 6-10 Tagen
27,99 €
inkl. MwSt.
PAYBACK Punkte
14 °P sammeln!
Diabetic macular edema (DME) is a major public health problem and is currently considered one of the leading causes of visual impairment in the world. DME is defined as a thickening of the macular region, related to an accumulation of extracellular fluid in the macula. The macula is the part of the eye responsible for central and fine vision (the part that allows us to read and recognize faces).The management of diabetic macular edema is changing. The therapeutic arsenalIn the last decade, this has included the anti-VEGF class. Intravitreal injections of anti-VEGF have shown their long-lasting...
Diabetic macular edema (DME) is a major public health problem and is currently considered one of the leading causes of visual impairment in the world. DME is defined as a thickening of the macular region, related to an accumulation of extracellular fluid in the macula. The macula is the part of the eye responsible for central and fine vision (the part that allows us to read and recognize faces).The management of diabetic macular edema is changing. The therapeutic arsenalIn the last decade, this has included the anti-VEGF class. Intravitreal injections of anti-VEGF have shown their long-lasting and proven efficacy in DME, in addition to improving peripheral diabetic retinopathy, and all this with an excellent tolerance and in association with pan-retinal pan-coagulation.We insist through this work on the interest of adequate primary and secondary prevention before this advanced stage of diabetic maculopathy to avoid blindness related to diabetic retinopathy and diabetic macular edema.
Andere Kunden interessierten sich für
